Brightenex™ from ZO® Medical Features New Oleosome Technology
Brightenex™ becomes the first product to market this advanced delivery system targeting hyperpigmentation and sun damage
Irvine, CA—May 14, 2012—ZO Skin Health, Inc. is delighted to reveal that the new ZO® Medical Brightenex™ skin brightener and correcting crème incorporates revolutionary Oleosome technology to deliver superior results as a safer alternative to hydroquinone for brighter and more even toned skin.
ZO® Medical’s Brightenex™ is bioengineered to target all four stages of skin discoloration through a patented, bio-vectored, micro-sphere delivery system. Experts recommend Brightenex™ as the first course in effectively treating hyperpigmentation.
Dr. Zein Obagi says "Move over Hydroqinone! ZO Skin Health, Inc. has found a new way to inhibit melanogenisis and reverse hyper pigmentation."
Brightenex™ is positioned to lead the category of topical hyperpigmentation solutions. It is the first commercial product launch that stabilizes pure retinol (1.0%), melanin inhibitors and antioxidants with natural, patented Oleosome technology. Oleosomes are microspheres of antioxidant-rich emollient oils and vitamins found naturally in plant seeds like almond and safflower. As these microspheres release, they provide immediate moisturization benefits to skin. By stabilizing and delivering retinol, Oleosome technology also provides a delayed release of active ingredients, reducing potential irritation while improving performance.
“We expect Brightenex™ to be one of our key selling ZO® Medical products, out pacing conventional hydroquinone,” says Deborah Tomes, Vice President of Domestic and International Marketing. “It's a revolutionary formula that was developed under the direction of Dr. Obagi."
Brightenex™ retails for $110. ZO® Medical products are exclusively available through leading physician practices throughout the U.S. and Canada.